echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Medical News > Latest Medical News > China Resources Double Crane: Subsidiary Linezolid Tablets Obtained Drug Registration Certificate

    China Resources Double Crane: Subsidiary Linezolid Tablets Obtained Drug Registration Certificate

    • Last Update: 2021-08-11
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    On June 23, China Resources Shuanghe stated that its wholly-owned subsidiary, China Resources Secco Pharmaceutical Co.


    The drug is used to treat specific microbial sensitive strains: hospital-acquired pneumonia; community-acquired pneumonia; complicated skin and skin and soft tissue infections, including diabetic foot infections without osteomyelitis; uncomplicated skin and skin and soft tissue infections ; Vancomycin-resistant Enterococcus faecium infection


    The original linezolid tablets were developed by Pfizer Pharmaceuticals in the United States.


    In the domestic market, according to the information on the website of the State Food and Drug Administration, there are 6 linezolid tablet manufacturers that have been approved for listing in mainland China


    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.